BioReperia

INVESTOR OVERVIEW | 2026

Every cancer patient is different. Their treatment should be too.

ZTX® PREDICT tests patient-derived tumours in living zebrafish models to provide a functional drug-response readout within five days.

5 DAYS	370	€2.7M
Biopsy to readout	Patients in clinical cohorts	Cumulative sales

A PLATFORM BUILT OVER 10 YEARS

ZTX® TECHNOLOGY

In vivo models • HuginMunin • 5-day data

CLINICAL EVIDENCE

370 patients tested
>500 biopsies overall

QUALITY & OPERATIONS

ISO 13485 QMS
QC-controlled lab

PROPRIETARY ASSETS

Workflows & software
Retained raw data

COMMERCIAL TRACTION

Recurring customers
15+ countries

ZTX® PREDICT – Bladder cancer

Prospective validation • IVDR • Market entry

WHY NOW

Bladder cancer is the lead indication. The next investment funds clinical and regulatory evidence, building on established technology and commercial operations.

THE INVESTMENT OPPORTUNITY

€5M

Funding prospective bladder cancer validation, IVDR progression and European/US market preparation.

THE VALUE CREATION PATH

01 Clinical validation

02 Regulatory milestones

03 Commercial launch

BioReperia AB | Linköping, Sweden | www.bioreperia.com

Clinical performance remains subject to prospective validation. Regulatory milestones and launch timing are forward-looking plans.